Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on advancing mental health treatments, has announced its participation in the Jefferies Global Healthcare Conference set for June 3, 2026. During the conference, the management team will engage in a fireside chat at 12:45 PM ET, discussing the company's innovative approaches to mental health care. A live audio webcast of this session will be available on the Investors section of the Compass Pathways website, with a replay accessible for 30 days post-event. Compass Pathways is committed to enhancing patient access to evidence-based mental health innovations, particularly through its investigational treatment, COMP360, which utilizes synthetic psilocybin. This treatment has been designated as a Breakthrough Therapy by the US Food and Drug Administration (FDA) and has also received Innovative Licensing and Access Pathway (ILAP) designation in the UK for addressing treatment-resistant depression. The company, headquartered in London with a presence in New York, envisions a future where mental health is defined by the ability to thrive, not merely the absence of illness.